COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy

Protocol No
TAKEDA-TAK-P2002-AML
Principal Investigator
Ehab Atallah
Phase
II
Summary
The purpose of the study is to determine whether treatment with the investigational drug Pevonedistat, in combination with venetoclax and azacitidine, improves the length of survival as well as the length of time without worsening of the disease.
Description
Triple Combination of Pevonedistat & Venetoclax Plus Azacitidine in Adults with AML Who Are Unfit for Intensive Chemotherapy
Participating Institutions
Froedtert Hospital
Status
SRC APPROVAL